Development of PRPK Directed Phthalimides

Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide (Pom) bind to cereblon (CRBN) and trigger proteasomal degradation of neo-substrates IKZF1/3 leading to multiple myeloma (MM) cell apoptosis. Pomalidomide (Pom) also binds albeit weakly to p53-related protein kinase (PRPK, aka TP53RK), an understudied kinase reported to be associated with poor prognosis in MM patients. Here, we developed a series of IMiDs based on Pom and conducted a structure-activity relationship (SAR) study to identify a potent and selective PRPK binder. Structural analysis showed that IMiDs bind PRPK in a fundamentally different way from CRBN, and suggested specific derivatization to improve affinity. We employed a structure-guided strategy to develop compound TXM-02-118, which exhibited nanomolar affinityfor PRPK in binding assays, and showed high selectivity for PRPK over CRBN. Overall, the work represents an initial effort to develop tool compounds for studying PRPK. Moreover, it illustrates how a single class of molecules can use different recognition elements to bind diverse targets using fundamentally different binding poses. This has broad implications for chemical probe and lead compound selectivity profiling, and argues for more wide-spread use of global proteomics or similar methodologies.

[1]  E. Fischer,et al.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery , 2020, Nature Structural & Molecular Biology.

[2]  L. Jones,et al.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality. , 2020, Trends in pharmacological sciences.

[3]  Christopher J. Williams,et al.  Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix , 2019, Acta crystallographica. Section D, Structural biology.

[4]  D. Rhodes,et al.  Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers , 2019, Molecular Cancer Research.

[5]  M. Pybus,et al.  Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome: case report and review of the literature , 2019, BMC Nephrology.

[6]  Roland L. Dunbrack,et al.  Defining a new nomenclature for the structures of active and inactive kinases , 2019, Proceedings of the National Academy of Sciences.

[7]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[8]  C. Prasad,et al.  Nephrological and urological complications of homozygous c.974G>A (p.Arg325Gln) OSGEP mutations , 2018, Pediatric Nephrology.

[9]  N. Matsumoto,et al.  A familial case of Galloway-Mowat syndrome due to a novel TP53RK mutation: a case report , 2018, BMC Medical Genetics.

[10]  Yong-Yeon Cho,et al.  Targeting PRPK and TOPK for skin cancer prevention and therapy , 2018, Oncogene.

[11]  Weiya Ma,et al.  Targeting PRPK Function Blocks Colon Cancer Metastasis , 2018, Molecular Cancer Therapeutics.

[12]  Jeremy F. P. Ullmann,et al.  Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly , 2017, Nature Genetics.

[13]  A. Bode,et al.  The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis , 2017, EBioMedicine.

[14]  N. Munshi,et al.  p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. , 2017, Blood.

[15]  M. Graille,et al.  Crystal structures of the Gon7/Pcc1 and Bud32/Cgi121 complexes provide a model for the complete yeast KEOPS complex , 2015, Nucleic acids research.

[16]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[17]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[18]  Patrick Forterre,et al.  Functional assignment of KEOPS/EKC complex subunits in the biosynthesis of the universal t6A tRNA modification , 2013, Nucleic acids research.

[19]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[20]  W. Kabsch.  XDS , 2010, Acta crystallographica. Section D, Biological crystallography.

[21]  D. Durocher,et al.  Atomic structure of the KEOPS complex: an ancient protein kinase-containing molecular machine. , 2008, Molecular cell.

[22]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.